CVE-2024-34063

Degraded secret zeroization capabilities in vodozemac

Description

vodozemac is an implementation of Olm and Megolm in pure Rust. Versions 0.5.0 and 0.5.1 of vodozemac have degraded secret zeroization capabilities, due to changes in third-party cryptographic dependencies (the Dalek crates), which moved secret zeroization capabilities behind a feature flag and defaulted this feature to off. The degraded zeroization capabilities could result in the production of more memory copies of encryption secrets and secrets could linger in memory longer than necessary. This marginally increases the risk of sensitive data exposure. This issue has been addressed in version 0.6.0 and users are advised to upgrade. There are no known workarounds for this vulnerability.

Category

2.5
CVSS
Severity: Low
CVSS 3.1 •
EPSS 0.03%
Affected: matrix-org vodozemac
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2024-34063?
CVE-2024-34063 has been scored as a low severity vulnerability.
How to fix CVE-2024-34063?
To fix CVE-2024-34063, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-34063 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-34063 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-34063?
CVE-2024-34063 affects matrix-org vodozemac.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.